Alligator Bioscience Announces Poster Presentation on ATOR-4066 at the AACR Annual Meeting 2023

  • Presentation highlights potential of ATOR-4066 to induce strong anti-tumor responses in patients with CEACAM5-expressing tumors
  • Data strongly support further development of ATOR-4066 towards the clinic
  • Data further validate Neo-X-Prime™, Alligator’s platform for 3rd generation conditional CD40 agonists

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the company presented a poster on ATOR-4066, a Neo-X-Prime™ bispecific antibody (bsAb), at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.

The presentation, entitled "ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEA, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo", highlights how ATOR-4066 has the potential to induce strong anti-tumor responses in patients with carcinoembryonic antigen 5 (CEACAM5)-expressing tumors.

CEACAM5, a well described clinical target for cancer therapy, is a glycoprotein that is overexpressed on the cell surface of many cancers including colorectal, gastric, pancreatic, and non-small cell lung cancer, with limited expression in normal adult tissue. Thus, it is an ideal target for a tumor-directed bispecific conditional CD40 agonist like ATOR-4066.

The data demonstrate CEACAM5 expression in relevant indications and how ATOR-4066 induces:

  • CEACAM5-conditional CD40-activation of tumor-infiltrating immune cells in patient-derived dissociated tumor samples from indications with high CEACAM5 expression, including colorectal and gastric cancer
  • co-localization of CEACAM5-expressing tumor debris and CD40-expressing antigen presenting cells
  • strong in vivo anti-tumor efficacy and induction of immunological memory

"We are excited to be presenting new data from our novel Neo-X-Prime approach at this year's AACR meeting," said Søren Bregenholt, CEO of Alligator Bioscience. "We have already shown that simultaneously targeting CD40 and tumor associated antigens leads to superior anti-tumor immunity. These new data further demonstrate the ability of ATOR-4066 to remodel the immune microenvironment and, as it continues to show great potential in inducing strong anti-tumor responses in CEACAM5-expressing tumors, we remain committed to advancing ATOR-4066 towards the clinic."

Poster Presentation Details
Abstract Number: 2939
Title: ATOR-4066, a Neo-X-Prime™bispecific antibody targeting CD40 and CEO, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo
Date/Time: Monday 17 April, 2023, 1.30 – 5.00 pm EDT
Session: PO.IM01.12 – Therapeutic Antibodies 2
Presenter: Anette Sundstedt, Principal Scientist, Alligator Bioscience
Location: Orange County Convention Center, Poster Section 23, Poster Board 2939

Updated 2023-04-18